<DOC>
	<DOCNO>NCT01760642</DOCNO>
	<brief_summary>Identification evaluation endogenous marker assessment CYP3A activity female subject use metabolomics</brief_summary>
	<brief_title>Identification Evaluation Endogenous Markers Assessment CYP3A Activity</brief_title>
	<detailed_description>Eligibility participation study determine demographic information , medical history , physical examination , electrocardiogram ( ECG ) clinical laboratory test within 3 week study drug administration . Subjects suitable study admit Clinical Trials Center , Seoul National University Hospital day dose , overnight-fasted 9 p.m. Day -1 . Urine collection schedule 24 hour midazolam administration 24 hour administration . Subjects dose midazolam intravenous around 9 a.m. Day 1 . Subjects perform schedule procedure include clinical laboratory test , electrocardiogram pharmacokinetic sampling . Subjects discharge Day 2 visit Clinical Trials Center period 2 , ketoconazole administration . After 3 day ketoconazole administration , midazolam dosed ketoconazole Day 4 period 2 . Subjects perform schedule procedure period 3 rifampicin dose 9 day Day 10 period 3 midazolam dose rifampicin . After subject perform schedule procedure , study terminate 6-8 day end period 3 .</detailed_description>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Ketoconazole</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Age : Between 20 50 year age , inclusive Weight : Between 45 95 kg , within 17 28 Body Mass Index Menstruation cycle 21 35 without contraceptive Subject agree contraception study Subject reliable willing make available study period , willing follow study protocol , give write informed consent voluntarily History hypersensitive reaction medication ( midazolam , ketoconazole , rifampicin ) History significant clinical illness need medical caution , include cardiovascular , immunologic , hematologic , neuropsychiatric , respiratory , gastrointestinal , hepatic , renal disease chronic disease history evidence drug abuse A subject whose lab test result follow ; Liver function test ( AST , ALT , GGT , ALP , LDH , Total bilirubin ) &gt; 1.25 X upper limit reference range A subject whose SBP 140 mmHg 90 mmHg DBP 100 mmHg 50 mmHg Presence history drug abuse positive result urine drug screen test Blood donation 2 month apheresis 1 month study Use prescriptive medication , Korean traditional medication consider acceptable clinical investigator last 14 day period first dose , use OTC medication consider acceptable clinical investigator last 7 day period first dose ( use medication consider acceptable investigator , patient include ) Use alcohol 21 units/weeks Smoker smoke 10 cigarette per day Participation clinical trial drug within 60 day prior participation study Use grapefruit juice within 1 week first dose Use caffeine drink within 3 day first dose Subject pregnant breastfeeding Judged inappropriate study investigator</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>metabolite profile</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>CYP3A</keyword>
	<keyword>metabolomics</keyword>
</DOC>